New research studies surrounding this compound, specifically the 120 milligram formulation referred to as ZPHC, indicate a impressive effect on body mass reduction and associated chronic factors. Researchers believe that this dual agonist , targeting both GLP-1 and GIP pathways , may represent a substantial improvement in the treatment of obesity